|
"cho h"的相關文件
顯示項目 1-10 / 11 (共2頁)
1 2 > >>
每頁顯示[10|25|50]項目
| 國家衛生研究院 |
2025-07-31 |
Integrative analysis of lung adenocarcinoma across diverse ethnicities and exposures
|
Satpathy, S; Clark, NM; Chen, YJ; Hosseini, N; Chang, YH; Hsiao, Y; Lei, JT; Petralia, F; Chen, JS; Geffen, Y; Heiman, DI; Paul, I; Cho, H; Hollenberg, M; Marino, GB; Lin, KT; Mannan, R; White, CJ; Allen, J; Avanessian, SC; Kane, MH; Wolfe, A; Kinarivala, M; Liu, W; Anand, S; Lin, MW; Haines, M; Bergstrom, EJ; Hussey, G; Li, GX; Mani, DC; Fang, H; Jaehnig, EJ; Keshishian, H; Miller, B; Su, KY; Hsiao, YJ; Hsu, HH; Hsieh, MS; Hsu, KH; Monovoukas, A; Gohsman, S; Thorup, JR; Deng, Y; Akiyama, Y; Deng, E; Sheng-Wen Chen, E; Krek, A; Espinoza, R; Ma, W; Charytonowicz, D; Sebra, R; Lin, JH; Chen, YS; Hsu, YC; Lin, ZS; Chen, KC; Yeh, CW; Wang, YT; Lazar, AJ; Mesri, M; An, E; Zhang, X; Clauser, KR; Fenyö, D; Chinnaiyan, AM; Zhang, B; Ding, L; Ruggles, K; Newton, C; Zhang, H; Wang, P; Hostetter, G; Omenn, GS; Kumar-Sinha, C; Thiagarajan, M; Govindan, R; Paik, P; Parolia, A; Li, QK; Ma'ayan, A; Getz, GA; Dhanasekaran, SM; Robles, AI; Chang, GC; Yang, PC; Yu, SL; Chen, HY; Nesvizhskii, AI; Carr, SA; Mani, DR; Cieslik, MP; Chen, YJ; Gillette, MA |
| 淡江大學 |
2023-04-28 |
The roles of employee-employee collaboration and employee-customer collaboration in fitness service innovation: A comparison of frontline and non-frontline employees
|
Wang, F. J.;Chiu, W.;Tseng, K. F.;Cho, H. |
| 國立成功大學 |
2023 |
Detecting Adversarial Examples of Fake News via the Neurons Activation State
|
Tseng, F.;Zeng, J.;Cho, H.;Yeh, K.;Chen, Chen C. |
| 國立成功大學 |
2023 |
Effective Adversarial Examples Detection Improves Screw Detection in Dust Pollution Within Industry System
|
Tseng, F.;Zeng, J.;Chen, Chen C.;Cho, H. |
| 臺大學術典藏 |
2022-04-25T06:32:34Z |
Measurements of the branching fractions of Ξc0→ΛKS0, Ξc0→Σ0KS0, and Ξc0→Σ+K- decays at Belle
|
Li Y;Cui J;Jia S;Shen C;Adachi I;Ahn J;Aihara H;Al Said S;Asner D;Atmacan H;Aushev T;Ayad R;Babu V;Bahinipati S;Behera P;Belous K;Bennett J;Bessner M;Bhardwaj V;Bhuyan B;Bilka T;Bobrov A;Bodrov D;Bonvicini G;Borah J;Bozek A;Bra?ko M;Branchini P;Browder T;Budano A;Campajola M;?ervenkov D;Chang M.-C;Chang P;Chen A;Cheon B;Chilikin K;Cho H;Cho K;Cho S.-J;Choi S.-K;Choi Y;Choudhury S;Cinabro D;Cunliffe S;Das S;De Nardo G;De Pietro G;Dhamija R;Di Capua F;Dingfelder J;Dole?al Z;Dong T;Dossett D;Epifanov D;Ferber T;Frey A;Fulsom B;Garg R;Gaur V;Gabyshev N;Giri A;Goldenzweig P;Gu T;Gudkova K;Hadjivasiliou C;Halder S;Hartbrich O;Hayasaka K;Hayashii H;Hedges M;Hou W.-S;Hsu C.-L;Iijima T;Inami K;Inguglia G;Ishikawa A;Itoh R;Iwasaki M;Iwasaki Y;Jacobs W;Jang E.-J;Jin Y;Joo K;Kahn J;Kaliyar A;Kawasaki T;Kiesling C;Kim C;Kim D;Kim K.-H;Kim Y.-K;Kinoshita K;Kody? P;Konno T;Korobov A;Korpar S;Kovalenko E;Kri?an P;Kroeger R;Krokovny P;Kuhr T;Kumar M;Kumar R;Kumara K;Kuzmin A;Kwon Y.-J;Lai Y.-T;Lam T;Lange J;Laurenza M;Lee S;Li C;Li J;Li L;Li Y;Li Gioi L;Libby J;Lieret K;Liventsev D;Martini A;Masuda M;Matsuda T;Matvienko D;Meier F;Merola M;Metzner F;Miyabayashi K;Mizuk R;Mohanty G;Mussa R;Nakao M;Natkaniec Z;Natochii A;Nayak L;Nayak M;Niiyama M;Nisar N;Nishida S;Ogawa K;Ogawa S;Ono H;Oskin P;Pakhlov P;Pakhlova G;Pang T;Pardi S;Park S.-H;Patra S;Paul S;Pedlar T;Pestotnik R;Piilonen L;Podobnik T;Popov V;Prencipe E;Prim M;R?hrken M;Rostomyan A;Rout N;Russo G;Sahoo D;Sandilya S;Sangal A;Santelj L;Sanuki T;Savinov V;Schnell G;Schwanda C;Seino Y;Senyo K;Sevior M;Shapkin M;Sharma C;Shiu J.-G;Shwartz B;Singh J;Sokolov A;Solovieva E;Stani? S;Stari? M;Stottler Z;Strube J;Sumihama M;Sumiyoshi T;Takizawa M;Tamponi U;Tanida K;Tenchini F;Uchida M;Unno Y;Uno K;Uno S;Urquijo P;Usov Y;Van Tonder R;Varner G;Vinokurova A;Waheed E;Wang E;Wang M.-Z;Watanabe M;Watanuki S;Werbycka O;Won E;Yabsley B;Yan W;Yang S;Ye H;Yelton J;Yuan C;Zhai Y;Zhang Z;Zhilich V;Zhukova V.; Li Y; WEI-SHU HOU et al. |
| 臺大學術典藏 |
2021-01-28T01:06:20Z |
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYnote-061): a randomised, open-label, controlled, phase 3 trial
|
Shitara K.;?Zg?Ro?Lu M.;Bang Y.-J.;Di Bartolomeo M.;Mandal? M.;Ryu M.-H.;Fornaro L.;Olesi?Ski T.;Caglevic C.;Chung H.C.;Muro K.;Goekkurt E.;Mansoor W.;Mcdermott R.S.;Shacham-Shmueli E.;Chen X.;Mayo C.;Kang S.P.;Ohtsu A.;Fuchs C.S.;Lerzo G.;O'Connor J.M.;Mendez G.A.;Lynam J.;Tebbutt N.;Wong M.;Strickland A.;Karapetis C.;Goldstein D.;Vasey P.;Van Laethem J.-L.;Van Cutsem E.;Berry S.;Vincent M.;Muller B.;Rey F.;Zambrano A.;Guerra J.;Krogh M.;Baeksgaard L.;Yilmaz M.;Elme A.;Magi A.;Auvinen P.;Alanko T.;Moehler M.;Kunzmann V.;Seufferlein T.;Thuss-Patience P.;Goekkurt E.;Hoehler T.;Haag G.;Al-Batran S.-E.;Castro H.;Lopez K.;Aguilar Vasquez M.;Sandoval M.;Lam K.O.;Cuffe S.;Kelly C.;Geva R.;Shacham-Shmueli E.;Hubert A.;Beny A.;Brenner B.;Giuseppe A.;Falcone A.;Maiello E.;Passalacqua R.;Montesarchio V.;Hara H.;Chin K.;Nishina T.;Komatsu Y.;Machida N.;Hironaka S.;Satoh T.;Tamura T.;Sugimoto N.;Cho H.;Omuro Y.;Kato K.;Goto M.;Hyodo I.;Yoshida K.;Baba H.;Esaki T.;Furuse J.;Wan Mohammed W.Z.;Hernandez Hernandez C.;Casas Garcia J.;Dominguez Andrade A.;Clarke K.;Hjortland G.;Glenjen N.;Kubiatowski T.;Jacek J.;Wojtukiewicz M.;Lazarev S.;Lancukhay Y.;Afanasayev S.;Moiseyenko V.;Kostorov V.;Protsenko S.;Shirinkin V.;Sakaeva D.;Fadeeva N.;Yong W.P.;Ng C.H.M.;Robertson B.;Rapaport B.;Cohen G.;Dreosti L.;Ruff P.;Jacobs C.;Landers G.;Szpak W.;Roh S.-Y.;Lee J.;Kim Y.H.;Bang Y.-J.;Chung H.C.;Ryu M.-H.;Alsina Maqueda M.;Longo Munoz F.;Cervantes Aguilar A.;Aranda Aguilar E.;Garcia Alfonso P.;Rivera F.;Feliu Batle J.;Pazo Cid R.;Kun-Huei Yeh;Chen J.-S.;Chao Y.;Yen C.-J.;?Zg?Ro?Lu M.;Kara O.;Yalcin S.;Hochhauser D.;Chau I.;Benson A.;Shankaran V.;Shaib W.;Philip P.;Sharma V.;Siegel R.;Sun W.;Wainberg Z.;George B.;Bullock A.;Myrick S.;Faruol J.;Siegel R.;Larson T.;Becerra C.;Ratnam S.;Richards D.A.;Riche S.L.;Keynote-061 Investigators; Shitara K.; ?zg?ro?lu M.; Bang Y.-J.; Di Bartolomeo M.; Mandal? M.; Ryu M.-H.; Fornaro L.; Olesi?ski T.; Caglevic C.; Chung H.C.; Muro K.; Goekkurt E.; Mansoor W.; McDermott R.S.; Shacham-Shmueli E.; Chen X.; Mayo C.; Kang S.P.; Ohtsu A.; Fuchs C.S.; Lerzo G.; O'Connor J.M.; Mendez G.A.; Lynam J.; Tebbutt N.; Wong M.; Strickland A.; Karapetis C.; Goldstein D.; Vasey P.; Van Laethem J.-L.; Van Cutsem E.; Berry S.; Vincent M.; Muller B.; Rey F.; Zambrano A.; Guerra J.; Krogh M.; Baeksgaard L.; Yilmaz M.; Elme A.; Magi A.; Auvinen P.; Alanko T.; Moehler M.; Kunzmann V.; Seufferlein T.; Thuss-Patience P.; Goekkurt E.; Hoehler T.; Haag G.; Al-Batran S.-E.; Castro H.; Lopez K.; Aguilar Vasquez M.; Sandoval M.; Lam K.O.; Cuffe S.; Kelly C.; Geva R.; Shacham-Shmueli E.; Hubert A.; Beny A.; Brenner B.; Giuseppe A.; Falcone A.; Maiello E.; Passalacqua R.; Montesarchio V.; Hara H.; Chin K.; Nishina T.; Komatsu Y.; Machida N.; Hironaka S.; Satoh T.; Tamura T.; Sugimoto N.; Cho H.; Omuro Y.; Kato K.; Goto M.; Hyodo I.; Yoshida K.; Baba H.; Esaki T.; Furuse J.; Wan Mohammed W.Z.; Hernandez Hernandez C.; Casas Garcia J.; Dominguez Andrade A.; Clarke K.; Hjortland G.; Glenjen N.; Kubiatowski T.; Jacek J.; Wojtukiewicz M.; Lazarev S.; Lancukhay Y.; Afanasayev S.; Moiseyenko V.; Kostorov V.; Protsenko S.; Shirinkin V.; Sakaeva D.; Fadeeva N.; Yong W.P.; Ng C.H.M.; Robertson B.; Rapaport B.; Cohen G.; Dreosti L.; Ruff P.; Jacobs C.; Landers G.; Szpak W.; Roh S.-Y.; Lee J.; Kim Y.H.; Bang Y.-J.; Chung H.C.; Ryu M.-H.; Alsina Maqueda M.; Longo Munoz F.; Cervantes Aguilar A.; Aranda Aguilar E.; Garcia Alfonso P.; Rivera F.; Feliu Batle J.; Pazo Cid R.; KUN-HUEI YEH; Chen J.-S.; Chao Y.; Yen C.-J.; ?zg?ro?lu M.; Kara O.; Yalcin S.; Hochhauser D.; Chau I.; Benson A.; Shankaran V.; Shaib W.; Philip P.; Sharma V.; Siegel R.; Sun W.; Wainberg Z.; George B.; Bullock A.; Myrick S.; Faruol J.; Siegel R.; Larson T.; Becerra C.; Ratnam S.; Richards D.A.; Riche S.L.; KEYnote-061 investigators |
| 國立成功大學 |
2019 |
Safety and efficacy of nivolumab in combination with s-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: Interim results of a randomized, phase II trial (a
|
Boku, N.;Ryu, M.-H.;Kato, Kato K.;Chung, H.C.;Minashi, K.;Lee, K.-W.;Cho, H.;Kang, W.K.;Komatsu, Y.;Tsuda, M.;Yamaguchi, K.;Hara, Hara H.;Fumita, S.;Azuma, M.;Chen, L.-T.;Kang, Y.-K. |
| 國家衛生研究院 |
2018-12-19 |
Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: Interim results of a randomized, phase 2 trial (AT
|
Boku, N;Ryu, MH;Kato, K;Chung, HC;Minashi, K;Lee, KW;Cho, H;Kang, WK;Komatsu, Y;Tsuda, M;Yamaguchi, K;Hara, H;Fumita, S;Azuma, M;Chen, LT;Kang, YK |
| 臺大學術典藏 |
2018-09-10T03:28:34Z |
GaN electronics for high power, high temperature applications
|
Pearton, SJ; Ren, F; Zhang, AP; Dang, G; Cao, XA; Cho, H; Abernathy, CR; Han, J; Baca, AG; Monier, C; others; MINGHWEI HONG |
| 國家衛生研究院 |
2017-09 |
Interim safety and clinical activity of nivolumab (Nivo) in combination with S-1/capecitabine plus oxaliplatin in patients (pts) with previously untreated unresectable advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: part 1 study of ATTRACTION-04 (ONO-4538-37)
|
Kang, YK;Kato, K;Chung, HC;Minashi, K;Lee, KW;Cho, H;Kang, WK;Komatsu, Y;Tsuda, M;Yamaguchi, K;Hara, H;Fumita, S;Azuma, M;Boku, N;Chen, LT |
顯示項目 1-10 / 11 (共2頁)
1 2 > >>
每頁顯示[10|25|50]項目
|
